SCHEMBL8322327

SCHEMBL8322327

O=C(O)c1c(C23CC4CC(CC(C4)C2)C3)cc2ccccc2c1-c1ccc(O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
THRB P10828 1/20 0.46
RECQL P46063 1/20 0.46
NR2E1 Q9Y466 1/20 0.46
RARB P10826 8/20 0.44
RARG P13631 7/20 0.44
RARA P10276 6/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GPR84 Q9NQS5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29929549 0.87 KMT2A (0.47) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL8322639 0.87 KMT2A (0.47) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL8322293 0.86 RARB (0.43) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL17323573 0.80 MEN1 (0.45) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL9317805 0.80 RARB (0.54) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL8766838 0.73 MEN1 (0.35) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL9317943 0.73 WDR5 (0.51) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL7744702 0.73 RARB (0.58) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL13004815 0.71 NQO2 (0.46) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL8323852 0.71 MEN1 (0.41) MEN1KMT2ATHRBRECQLNR2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5942531-A Phenolic/naphtholic retinoids for promoting skin/exoskeleton pigmentation CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) 1999-08-24 US claimed
US-5854292-A Stimulating the differentiation of preadipocytic cells and therapies based thereon CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-12-29 US claimed
US-5827897-A INSULIN-RESISTANCE IN A MAMMAL TREATED BY ADMINISTERING A SYNERGISTIC MIXTURE OF A RETINOID AND A FATTY ACID; ANTIDIABETIC AGENTS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-10-27 US claimed
US-5728739-A LIGANDS WITH AFFINITY FOR RETINOIC ACID RECEPTORS IN SYNERGISTIC COMBINATION WITH A FATTY ACID, TREATMENT OF DIABETES, CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-03-17 US claimed
CN-1104896-C 'Gamma'-RAR antagonist ligand or 'alpha'-RAR agonist ligand as apoptosis inhibitor GALDERMA RECH DERMATOLOGIQUE (FR) 2003-04-09 CN disclosed
US-5942531-A Phenolic/naphtholic retinoids for promoting skin/exoskeleton pigmentation CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) 1999-08-24 US disclosed
CN-1203529-A RAR-gamma antagonist ligands or RAR-alpha agonist ligands as apoptosis inhibitors CIRD GALDERMA (FR) 1998-12-30 CN disclosed
US-5854292-A Stimulating the differentiation of preadipocytic cells and therapies based thereon CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-12-29 US disclosed
US-5827897-A INSULIN-RESISTANCE IN A MAMMAL TREATED BY ADMINISTERING A SYNERGISTIC MIXTURE OF A RETINOID AND A FATTY ACID; ANTIDIABETIC AGENTS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-10-27 US disclosed
US-5767148-A 4-((5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHYL) CARBONYLBENZOIC ACID ETHYLENE ACETAL AND 4-((5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHYL) CARBOXYLAMIDOBENZOIC ACID HAVING RETINOID ACTIVITYP; LEUKEMIA CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-06-16 US disclosed
US-5728739-A LIGANDS WITH AFFINITY FOR RETINOIC ACID RECEPTORS IN SYNERGISTIC COMBINATION WITH A FATTY ACID, TREATMENT OF DIABETES, CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-03-17 US disclosed